A randomized, placebo‐controlled study to evaluate safety and pharmacokinetics of inhaled ribavirin

Ribavirin is an inosine monophosphate dehydrogenase inhibitor. Studies suggest ribavirin aerosol could be a safe and efficacious treatment option in the fight against coronaviruses. However, current treatment is long (12–18 h per day, 3–7 days), limiting clinical utility. A reduction in treatment ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Couroux, Peter, Brkovic, Alexandre, Vittitow, Jason L., Israel, Robert J., Pamidi, Chinna, Patel, Jignesh, Barakat, Maxime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468560/
https://www.ncbi.nlm.nih.gov/pubmed/35677972
http://dx.doi.org/10.1111/cts.13350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468560/
https://www.ncbi.nlm.nih.gov/pubmed/35677972
http://dx.doi.org/10.1111/cts.13350

Ejemplares similares